Molecular Templates
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 62
- Market Cap
- -
- Website
- http://www.mtem.com
- Introduction
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and is headquartered in Austin, TX.
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
- Conditions
- Renal Cell CarcinomaMesotheliomaCervical CancerMelanomaMismatch Repair DeficiencyUrothelial CarcinomaMicrosatellite Instability HighNon Small Cell Lung CancerEsophageal Squamous Cell CarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06034860
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Horizon Oncology Research, LLC, Lafayette, Indiana, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
- Conditions
- Advanced Solid TumorSquamous Cell Carcinoma of Head and NeckNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04795713
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Study of MT-5111 in HER2-positive Solid Tumors
- Conditions
- HER2-positive Solid Cancers
- Interventions
- Drug: MT-5111 (experimental study drug)
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04029922
- Locations
- 🇺🇸
Mayo Clinic (Arizona), Phoenix, Arizona, United States
🇺🇸St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04017130
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸Miami University, Miami, Florida, United States
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03645395
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Boca Raton Clinical Research, Plantation, Florida, United States
🇺🇸Rush University, Chicago, Illinois, United States
- Prev
- 1
- 2
- Next